On ECHEMI
Home > Drugs > Hainan Brilliant Pharmaceutical Co., Ltd.
Hainan Brilliant Pharmaceutical Co., Ltd.
  • Founded in:

    2004-07-29
  • Country:

    China China
  • Address:

    No. 4, Yaogu 1st Road, Haikou National High-tech Industrial Development Zone, Haikou City
  • Tax NO.:

    914600007603794713
  • Registered Funds:

    12.27100815 million yuan
  • Email:

Related Drugs
Methionine Vitamin B1 for Injection
This product is a compound preparation: the main ingredients are methionine and vitamin B1, methionine: L-2-amino-4 (methylthio) butyric acid, vitamin B1: 4-methyl-3-[(2-methyl-4-amino-5-pyrimidinyl)methyl]-5-(2-hydroxyethyl)thiazolidine hydrochloride.
Name Description Content CAS NO. Registered Holders
DL-Methionine

One of the eight essential amino acids for the human body, it combines with ATP to generate S-adenosine, promotes methylation of liver cell membrane phospholipids, reduces intrahepatic bile stasis, enhances transsulfurization, restores the physiological function of liver cells, promotes the disappearance of jaundice and recovery of liver function, supplies methyl groups to promote choline synthesis, promotes liver fat metabolism, protects the liver and detoxifies.

More

One of the eight essential amino acids for the human body, it combines with ATP to generate S-adenosine, promotes methylation of liver cell membrane phospholipids, reduces intrahepatic bile stasis, enhances transsulfurization, restores the physiological function of liver cells, promotes the disappearance of jaundice and recovery of liver function, supplies methyl groups to promote choline synthesis, promotes liver fat metabolism, protects the liver and detoxifies.

59-51-8 10
Thiamine chloride

It combines with pyrophosphate in the body to form a cocarboxylase, participating in the oxidative decarboxylation reaction of pyruvate and a-ketoglutarate in sugar metabolism, and is necessary for sugar metabolism.

More

It combines with pyrophosphate in the body to form a cocarboxylase, participating in the oxidative decarboxylation reaction of pyruvate and a-ketoglutarate in sugar metabolism, and is necessary for sugar metabolism.

59-43-8 9
Enoxacin Gluconate for Injection
The main ingredient of this product is enoxacin gluconate. Its chemical name is: 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid-D-gluconate monohydrate.
Name Description Content CAS NO. Registered Holders
ENOXACIN GLUCONATE

This product has a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative bacilli. It has good antibacterial activity against most bacteria of the Enterobacteriaceae family, including Citrobacter, Enterobacter cloacae, Enterobacter aerogenes, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. It often has antibacterial activity against multi-drug resistant bacteria. It has high antibacterial activity against penicillin-resistant Neisseria gonorrhoeae, enzyme-producing Haemophilus influenzae and Moraxella. It has antibacterial activity against most strains of Pseudomonas such as Pseudomonas aeruginosa. It has antibacterial activity against methicillin-sensitive Staphylococcus aureus, and only moderate antibacterial activity against Streptococcus pneumoniae, hemolytic Streptococcus and Enterococcus faecalis. It has good antimicrobial effect against Chlamydia trachomatis, Mycoplasma, Legionella, and also has antibacterial activity against Mycobacterium tuberculosis and atypical mycobacteria. It has poor antibacterial activity against anaerobic bacteria. Enoxacin is a bactericide that acts on the A subunit of bacterial DNA helicase, inhibiting DNA synthesis and replication, leading to bacterial death.

More

This product has a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative bacilli. It has good antibacterial activity against most bacteria of the Enterobacteriaceae family, including Citrobacter, Enterobacter cloacae, Enterobacter aerogenes, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. It often has antibacterial activity against multi-drug resistant bacteria. It has high antibacterial activity against penicillin-resistant Neisseria gonorrhoeae, enzyme-producing Haemophilus influenzae and Moraxella. It has antibacterial activity against most strains of Pseudomonas such as Pseudomonas aeruginosa. It has antibacterial activity against methicillin-sensitive Staphylococcus aureus, and only moderate antibacterial activity against Streptococcus pneumoniae, hemolytic Streptococcus and Enterococcus faecalis. It has good antimicrobial effect against Chlamydia trachomatis, Mycoplasma, Legionella, and also has antibacterial activity against Mycobacterium tuberculosis and atypical mycobacteria. It has poor antibacterial activity against anaerobic bacteria. Enoxacin is a bactericide that acts on the A subunit of bacterial DNA helicase, inhibiting DNA synthesis and replication, leading to bacterial death.

104142-71-4 26
Azithromycin for injection
Main ingredients: The main ingredient of this product is azithromycin. Its chemical name is (2R, 3S, 4R, 5R, 8R, 10R, 11R, 12S, 13S, 14R)-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-beta;-D-xyl-pyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one. Structural formula: (see azithromycin dry suspension) Molecular formula: C38H72N2O12 Molecular weight: 749
Name Description Content CAS NO. Registered Holders
Azithromycin

Azithromycin is a 15-membered macrolide antibiotic. In vitro tests have shown that azithromycin has antibacterial effects on a variety of common clinical pathogens, including: Gram-positive aerobic bacteria, Staphylococcus aureus, Streptococcus pyogenes (group A beta; hemolytic streptococci), pneumonia (streptococci), a-hemolytic streptococci (grass-green streptococci) and other streptococci, diphtheria (rod-shaped) bacilli. This product shows cross-resistance to erythromycin-resistant Gram-positive bacteria, including fecal streptococci (enterococci) and various methicillin-resistant Staphylococcus strains.

More

Azithromycin is a 15-membered macrolide antibiotic. In vitro tests have shown that azithromycin has antibacterial effects on a variety of common clinical pathogens, including: Gram-positive aerobic bacteria, Staphylococcus aureus, Streptococcus pyogenes (group A beta; hemolytic streptococci), pneumonia (streptococci), a-hemolytic streptococci (grass-green streptococci) and other streptococci, diphtheria (rod-shaped) bacilli. This product shows cross-resistance to erythromycin-resistant Gram-positive bacteria, including fecal streptococci (enterococci) and various methicillin-resistant Staphylococcus strains.

83905-01-5 39
Azithromycin for injection
Main ingredients: The main ingredient of this product is azithromycin. Its chemical name is (2R, 3S, 4R, 5R, 8R, 10R, 11R, 12S, 13S, 14R)-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-beta;-D-xyl-pyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one. Structural formula: (see azithromycin dry suspension) Molecular formula: C38H72N2O12 Molecular weight: 749
Name Description Content CAS NO. Registered Holders
Azithromycin

Azithromycin is a 15-membered macrolide antibiotic. In vitro tests have shown that azithromycin has antibacterial effects on a variety of common clinical pathogens, including: Gram-positive aerobic bacteria, Staphylococcus aureus, Streptococcus pyogenes (group A beta; hemolytic streptococci), pneumonia (streptococci), a-hemolytic streptococci (grass-green streptococci) and other streptococci, diphtheria (rod-shaped) bacilli. This product shows cross-resistance to erythromycin-resistant Gram-positive bacteria, including fecal streptococci (enterococci) and various methicillin-resistant Staphylococcus strains.

More

Azithromycin is a 15-membered macrolide antibiotic. In vitro tests have shown that azithromycin has antibacterial effects on a variety of common clinical pathogens, including: Gram-positive aerobic bacteria, Staphylococcus aureus, Streptococcus pyogenes (group A beta; hemolytic streptococci), pneumonia (streptococci), a-hemolytic streptococci (grass-green streptococci) and other streptococci, diphtheria (rod-shaped) bacilli. This product shows cross-resistance to erythromycin-resistant Gram-positive bacteria, including fecal streptococci (enterococci) and various methicillin-resistant Staphylococcus strains.

83905-01-5 39
Furosemide Injection
The main ingredient of this product: furosemide. Chemical name: 2-[(2-furanmethyl)amino]-5-(aminosulfonyl)-4-chlorobenzoic acid. Molecular formula: C12H11ClN2O5S Molecular weight: 330.75 Excipients: sodium chloride, sodium hydroxide, water for injection
Name Description Content CAS NO. Registered Holders
Furosemide

1. Effect on water and electrolyte excretion: It can increase the excretion of water, sodium, chloride, potassium, calcium, magnesium, phosphorus, etc.; mainly by inhibiting the active reabsorption of NaCl by the thick-walled segment of the renal tubular loop, reducing the osmotic pressure gradient difference of the medullary interstitial fluid, resulting in increased excretion of water, Na+, and Cl-; promoting increased Na+-K+ and Na+-H+ exchange in the distal tubule, increasing the excretion of K+ and H+; inhibiting the reabsorption of Ca2+ and Mg2+ by the loop of Henle and increasing their excretion. Short-term use of the drug can increase uric acid excretion, and long-term use of the drug can cause hyperuricemia. 2. Effect on hemodynamics: Furosemide can inhibit the activity of prostaglandin degrading enzymes, increase the content of prostaglandin E2, and dilate blood vessels; increase renal blood flow, especially deep renal cortical blood flow; it is of great significance in the diuretic effect; dilate pulmonary capacitance veins, reduce pulmonary capillary permeability, reduce venous return, and reduce left ventricular end-diastolic pressure, which is helpful for the treatment of acute left heart failure; reduce pulmonary capillary permeability, providing a theoretical basis for the treatment of adult respiratory distress syndrome.

More

1. Effect on water and electrolyte excretion: It can increase the excretion of water, sodium, chloride, potassium, calcium, magnesium, phosphorus, etc.; mainly by inhibiting the active reabsorption of NaCl by the thick-walled segment of the renal tubular loop, reducing the osmotic pressure gradient difference of the medullary interstitial fluid, resulting in increased excretion of water, Na+, and Cl-; promoting increased Na+-K+ and Na+-H+ exchange in the distal tubule, increasing the excretion of K+ and H+; inhibiting the reabsorption of Ca2+ and Mg2+ by the loop of Henle and increasing their excretion. Short-term use of the drug can increase uric acid excretion, and long-term use of the drug can cause hyperuricemia. 2. Effect on hemodynamics: Furosemide can inhibit the activity of prostaglandin degrading enzymes, increase the content of prostaglandin E2, and dilate blood vessels; increase renal blood flow, especially deep renal cortical blood flow; it is of great significance in the diuretic effect; dilate pulmonary capacitance veins, reduce pulmonary capillary permeability, reduce venous return, and reduce left ventricular end-diastolic pressure, which is helpful for the treatment of acute left heart failure; reduce pulmonary capillary permeability, providing a theoretical basis for the treatment of adult respiratory distress syndrome.

54-31-9 49
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.